-
公开(公告)号：US20220370558A1
公开(公告)日：2022-11-24
申请号：US17622225
申请日：2020-06-23
Inventor： Michal Lotem , Emma Hajaj , Galit Eisenberg
IPC: A61K38/17 , A61K39/395 , A61K35/17 , A61P35/00
Abstract: The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.
-
Patent Agency Ranking
公开(公告)号：US11530251B2
公开(公告)日：2022-12-20
申请号：US16417048
申请日：2019-05-20
Inventor： Abraham Rutenberg , Ronny Uzana , Michal Lotem , Arthur Machlenkin , Galit Eisenberg , Tamar Peretz-Yablonsky , Shoshana Frankenburg , Roni Engelstein
IPC: C07K14/705 , A61K38/17 , A61K35/17 , A61P35/00 , C12N5/0783 , A61K39/39 , A61K39/395 , A61K45/06 , C07K16/28 , A61K39/00
Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
-
公开(公告)号：US20220347203A1
公开(公告)日：2022-11-03
申请号：US17622224
申请日：2020-06-23
Inventor： Michal Lotem , Emma Hajaj , Galit Eisenberg
IPC: A61K31/712 , C12N15/113 , A61K35/17
Abstract: The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.
-
公开(公告)号：US09301998B2
公开(公告)日：2016-04-05
申请号：US14081761
申请日：2013-11-15
Inventor： Tamar Peretz , Michal Lotem , Arthur Machlenkin , Shoshana Frankenburg , Inna Ben David , Anna Kuznetz , Yael Gelfand , Galit Eisenberg , Merav Darash Yahana
IPC: A61K39/00 , C12N5/09 , C12Q1/68 , G01N33/574
CPC classification number: A61K39/0011 , A61K2039/5152 , C12N5/0693 , C12Q1/6886 , G01N33/57492
Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
Abstract translation: 本发明涉及癌症免疫治疗，特别涉及同种异体肿瘤细胞疫苗。 根据一些实施方案，本发明提供可用作治疗性细胞疫苗组合物的新型细胞系。 本发明还提供了有利的筛选方法和手段，用于鉴定适合用部分人白细胞抗原（HLA）匹配的同种异体细胞疫苗治疗的患者。 进一步提供用于增殖性疾病的治疗组合物和方法。
-
公开(公告)号：US10344073B2
公开(公告)日：2019-07-09
申请号：US15110111
申请日：2015-01-08
Inventor： Abraham Rutenberg , Ronny Uzana , Michal Lotem , Arthur Machlenkin , Galit Eisenberg , Tamar Peretz-Yablonsky , Shoshana Frankenburg , Roni Engelstein
IPC: C07K14/705 , C07K14/725 , A61K39/39 , A61K39/395 , A61K35/17 , C12N5/0783 , A61K45/06 , C07K16/28 , A61K39/00
Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
-
公开(公告)号：US10064927B2
公开(公告)日：2018-09-04
申请号：US15051205
申请日：2016-02-23
Inventor： Tamar Peretz , Michal Lotem , Arthur Machlenkin , Shoshana Frankenburg , Inna Ben David , Anna Kuznetz , Yael Gelfand , Galit Eisenberg , Merav Darash Yahana
IPC: A61K39/00 , C12N5/09 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
-
-
-
-
-
Search Results
6
records
(took 0.021 seconds)
